Implication and Genetic Variations on Lipid Profile of the Fasting Respondent

Authors: Rohayu Izanwati M. R., Muhamad Ridhwan M. R., Abbe Maleyki M. J., Ahmad Zubaidi A. L., Zahri M. K.

Abstract:

PPARs function as regulators of lipid and lipoprotein metabolism. The aim of the study was to compare the lipid profile between two phases of fasting and to examine the frequency and relationship of peroxisome proliferator-activated receptor, PPARα gene polymorphisms to lipid profile in fasting respondents. We conducted a case-control study protocol, which included 21 healthy volunteers without gender discrimination at the age of 18 years old. 3 ml of blood sample was drawn before the fasting phase and during the fasting phase (in Ramadhan month). 1ml of serum for the lipid profile was analyzed by using the automated chemistry analyser (Olympus, AU 400) and the data were analysed using the Paired T-Test (SPSS ver.20). DNA was extracted and PCR was conducted utilising 6 sets of primer. Primers were designed within 6 exons of interest in PPARα gene. Genetic and metabolic characteristics of fasting respondents and controls were estimated and compared. Fasting respondents were significantly have lowered the LDL levels (p=0.03). There were no polymorphisms detected except in exon 1 with 5% of this population study respectively. The polymorphisms in exon 1 of the PPARα gene were found in low frequency. Regarding the 1375G/T and 1386G/T polymorphisms in the exon 1 of the PPARα gene, the T-allele in fasting phase had no association with the decreased LDL levels (Fisher Exact Test). However this association is more promising when the sample size is larger in order to elucidate the precise impact of the polymorphisms on lipid profile in the population. In conclusion, the PPARα gene polymorphisms do not appear to affect the LDL of fasting respondents.

Keywords: Fasting, LDL, Peroxisome proliferator activated receptor alpha (PPAR-α), Polymorphisms.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1091122

References:

[1] R. Bordet, T. Ouk, O. Petrault et al., "PPAR: A New Pharmacological Target for Neuroprotection in Stroke and Neurodegenerative Diseases.” Biochemical Society Transactions, vol. 34, no. 6, pp. 1341–1346, 2006.
[2] D. M. Flavell, Y. Jamshidi, E. Hawe et al., "Peroxisome Proliferator-Activated Receptor α Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease.” Circulation, vol. 105, no. 12, pp. 1440–1445, 2002.
[3] I. C. Ozturk and A. A. Killeen, "An Overview of Genetic Factors Influencing Plasma Lipid Levels and Coronary Artery Disease Risk.” Archives of Pathology and Laboratory Medicine, vol. 123, no. 12, pp. 1219–1222, 1999.
[4] A. M. Thannoun and E .S. Mahmoud, "Effect of Fasting in Ramadan on Blood Glucose and Lipid Profile.” Mesopotamia Journal of Agriculture, vol. 38, no. 2, 2010.
[5] J. Rehman and M. Shafiq , "Changes in Blood Glucose and Lipid Profile during Ramadan Fasting.” J Ayub Med Coll Abbottabad, vol. 12, no. 3, pp. 13-15, 2000.
[6] A. Aldouni et al., "Fasting during Ramadan Induces a Marked Increase in High- Density Lipoprotein Cholesterol and Decrease in Low-Density Lipoprotein Cholesterol.” Annals of Nutrition and Metabolism, vol. 41, pp. 242-249, 1997.
[7] S. A. Saleh, A. Elsharouni, B. Cherian, and M. Mourou, "Effects of Ramadan Fasting on Waist Circumference, Blood Pressure, Lipid Profile, and Blood Sugar on a Sample of Healthy Kuwaiti Men and Women.” Mal Journal Nutrition, vol. 11, no.2, pp. 143-150, 2005.
[8] Reinhard et al. "Association between PPAR-Alpha Gene Polymorphisms and Myocardial Infarction,” Clinical Science, doi: 10.1042/CS2007039. 2010.
[9] A. C. Frazier-Wood, J. M. Ordovas, R. J. Straka, J. E. Hixson, I. B. Borecki, H. K. Tiwari and D. K. Arnett, "The PPAR Alpha Gene is Associated with Triglyceride, Low Density Cholesterol and Inflammation Marker Response to Fenofibrate Intervention: The GOLDN study.” The Pharmacogenomics Journal, doi: 10.1038/tpj.2012.
[10] D. Qujeq, K. Bijani, K. Kalavi, J. Mohiti, H. Aliakbarpour. "Effects of Ramadan Fasting on Serum Low Density and High Density Lipoprotein Cholesterol Concentrations.” Ann Saudi Med, vol. 22 (5-6), pp. 297-299, 2002.
[11] T. Coll, R. Rodriguez-Calvo, E. Barroso, L. Serrano, E. Eyre, X. Palomer, M. Vazquez-Carrera "Peoxisome Proliferator-Activated Receptor (PPAR)β/δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome.” Current Molecular Pharmacology, vol. 2, pp. 46-55, 2009.
[12] J. Uthurralt, et al. "PPARα Underlies Variation in Serum Triglycerides and Subcutaneous Fat Volume in Young Males.” BMC Medical Genetics, 8:55 doi:10.1 186/1471 -2350-8-55. 2007.
[13] Marie-Claude Vohl, et al. "Molecular Scanning of the Human PPARα Gene: Association of the L162V Mutation with hyperapobetalipoproteinemia”. Journal of Lipid Research Vol 41, pp. 945-952, 2000.